Measuring the Costs and Benefits of New Biomarkers for Prostate Cancer Screening
Prostate cancer is the most common solid tumor in American men. At its current level of prevalence, the American Cancer Society (ACS) estimates one in six men will be diagnosed with prostate cancer during their lifetimes. In the past, screening relied heavily on the prostate-specific antigen (PSA) test. However, concerns about the potential for false positive and false negative results have called into question whether the benefits of PSA tests outweigh the costs and harms of testing. The imminent release of several new biomarkers in the U.S. has added to the complexity of decision making about whether and when these new tests should be used. This MCubed project involves the building of quantitative models, based on data collected through systematic review of the literature, and through the National Cancer Institute Early Detection Network (NCI-EDRN), to investigate mortality, quality of life, and cost implications of implementing these new biomarkers.
$205,000 grant from the National Science Foundation